David Thomas
About David Thomas
David Thomas serves as the Director of Cachexia Discovery and Therapeutic Development at the Broad Institute of MIT & Harvard, where he has worked since 2007. He specializes in genomic sciences and predictive toxicogenomics to advance drug discovery and therapeutic applications for cancer cachexia.
Current Role at Broad Institute
David Thomas serves as the Director of Cachexia Discovery and Therapeutic Development at the Broad Institute of MIT & Harvard. He has held this position since 2015, contributing to advancements in understanding cancer cachexia. His work involves developing novel discovery platforms that utilize genomic sciences to address the challenges associated with this condition. Additionally, he has been a Physician Scientist at the Broad Institute since 2008, focusing on the intersection of clinical practice and research.
Previous Experience at Broad Institute
David Thomas has an extensive history at the Broad Institute of MIT & Harvard, where he worked as a Director of Cachexia Research and Therapeutic Development from 2007 to 2016. His initial role was as a Postdoctoral Fellow in the Cancer Program from 2007 to 2008. This experience laid the foundation for his current research initiatives and helped him develop expertise in cachexia and drug discovery.
Educational Background
David Thomas studied at the Yale University School of Medicine, where he gained significant knowledge in medical sciences. He also earned his MD from the University of Virginia School of Medicine. His educational background includes a focus on Functional Genomics, which he pursued during his postdoctoral studies at the Broad Institute. This academic training has informed his research and therapeutic development efforts.
Research Focus and Contributions
David Thomas's research primarily focuses on understanding the driving mediators of cancer cachexia. He aims to gain mechanistic insights into complex medical problems, which can lead to novel therapeutic applications. His work in predictive toxicogenomics enhances drug discovery efforts, allowing for more effective development of treatments for cancer cachexia and related conditions.